We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+66.45%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.11B
AUM Growth
+$907M
Cap. Flow
+$316M
Cap. Flow %
14.95%
Top 10 Hldgs %
69.55%
Holding
49
New
3
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
SPT icon
Sprout Social
SPT
+$147M
2
OYST
Oyster Point Pharma, Inc. Common Stock
OYST
+$104M
3
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$53.2M
4
LITS
Lite Strategy Inc
LITS
+$5.23M
5
ARDX icon
Ardelyx
ARDX
+$4.86M

Top Sells

Rank Stock Value
1
KA
Kineta, Inc. Common Stock
KA
+$4.7M
2
AKAO
Achaogen Inc
AKAO
+$63K

Sector Composition

Rank Sector Weight
1 Healthcare 86.26%
2 Technology 10.64%
3 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
1
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$288M 13.62%
6,138,797
– –
ALLK
2
DELISTED
Allakos
ALLK
$216M 10.23%
2,268,188
– –
SPT icon
3
Sprout Social
SPT
$534M
$145M 6.87%
+9,046,080
New +$147M
OYST
4
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$145M 6.85%
+5,925,287
New +$104M
CRSP icon
5
CRISPR Therapeutics
CRSP
$4.64B
$127M 6.02%
2,090,678
– –
ARDX icon
6
Ardelyx
ARDX
$1.24B
$121M 5.72%
16,135,047
+800,000
+5% +$4.86M
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.4B
$113M 5.33%
4,912,306
– –
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$108M 5.09%
4,377,518
– –
AUPH icon
9
Aurinia Pharmaceuticals
AUPH
$1.92B
$105M 4.96%
5,172,683
– –
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.72B
$103M 4.86%
4,187,801
– –
NET icon
11
Cloudflare
NET
$94.5B
$71.2M 3.37%
4,059,376
– –
MRSN
12
DELISTED
Mersana Therapeutics
MRSN
$68.6M 3.24%
478,546
– –
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$57.4M 2.72%
+4,362,986
New +$53.2M
DERM
14
DELISTED
Dermira, Inc.
DERM
$53.2M 2.51%
3,506,649
– –
CBIO
15
Crescent Biopharma
CBIO
$602M
$48.1M 2.27%
90,890
– –
PHAS
16
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$40.6M 1.92%
6,643,704
– –
SENS icon
17
Senseonics Holdings Inc
SENS
$254M
$28.4M 1.34%
1,544,413
– –
LITS
18
Lite Strategy Inc
LITS
$33.2M
$21.2M 1%
426,654
+140,625
+49% +$5.23M
ADAP
19
DELISTED
Adaptimmune Therapeutics
ADAP
$19M 0.9%
15,832,611
– –
OBSV
20
DELISTED
ObsEva SA Ordinary Shares
OBSV
$17.5M 0.83%
4,586,563
– –
AFMD
21
DELISTED
Affimed
AFMD
$16.8M 0.79%
612,649
+98,760
+19% +$2.64M
TRVI icon
22
Trevi Therapeutics
TRVI
$2.6B
$16.7M 0.79%
4,441,360
– –
AVEO
23
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$15.8M 0.75%
2,524,387
– –
GNCA
24
DELISTED
Genocea Biosciences, Inc.
GNCA
$15M 0.71%
7,225,676
– –
MRKR icon
25
Marker Therapeutics
MRKR
$20.2M
$14.4M 0.68%
500,000
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2019 Portfolio in Review

As of Q4 2019, NEA Management Company held 49 positions worth $2.11B, up 75% from $1.21B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

NEA Management Company deployed $316M of net new capital in Q4 2019, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Sprout Social: 9,046,080 shares worth $145M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the most notable exit was Kineta, Inc. Common Stock, an estimated $4.7M sold.

  • NEA Management Company's largest Q4 2019 buy was Sprout Social: 9,046,080 shares worth $145M.
  • NEA Management Company added most to Lite Strategy Inc in Q4 2019, an estimated $5.23M increase.
  • NEA Management Company fully exited Kineta, Inc. Common Stock in Q4 2019, selling an estimated $4.7M.
  • NEA Management Company's ten largest holdings make up 70% of its $2.11B portfolio in Q4 2019.
  • NEA Management Company opened 3 new positions and closed 2 in Q4 2019.
  • NEA Management Company's portfolio value rose 75% quarter-over-quarter to $2.11B.

Based on NEA Management Company's 13F filing for Q4 2019, filed 24 Jan 2020.